by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Slides:

Advertisements

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Advertisements

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications by Elias Campo, Steven H. Swerdlow, Nancy L.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma by Florian Scherer, David M. Kurtz, Aaron M. Newman, Henning.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses by Alain H. Rook, Gary S. Wood, Elisa K. Yoo,

Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma by Raija Ristamäki, Heikki Joensuu, Kimmo Lappalainen, Lasse.

Do HSCs divide asymmetrically?

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients by Nina.

Defects in DBA: more than meets the eye

Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease by Marijke R. Canninga-van Dijk, Hanneke.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Victor R. Gordeuk, Oswaldo L. Castro, and Roberto F. Machado

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Tax fingerprint in adult T-cell leukemia

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

Mechanisms of HIV-associated lymphocyte apoptosis

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for.

Fusion genes in cord blood

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

AIDS-Related Extranodal Non-Hodgkin's Lymphomas With Plasma Cell Differentiation by Antonino Carbone, Annunziata Gloghini, Vincenzo Canzonieri, Umberto.

Taking a leaf from the book of oral tolerance

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Paolo Strati, Michael J. Keating, William G. Wierda, Xavier C

by J. Rodriguez, M. A. Rodriguez, L. Fayad, P. McLaughlin, F. Swan, A

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell Transplantation Benjamin Kasenda, M.D., Elisabeth Schorb, M.D., Kristina.

by Michael F. Leahy, and J. Harvey Turner

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma by Hannes Kaufmann, Markus Raderer, Stefan Wöhrer,

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience by Daryl Tan, Sandra.

Lymphoma spread? Target CD47-SIRPα!

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,

by George Z. Rassidakis, Mauricio P. Oyarzo, and L. Jeffrey Medeiros

Anergy: the CLL cell limbo

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Overall survival by SCT versus observation in first complete remission

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Efficient Stem Cell Collection after Modified Cisplatin-Based Mobilization Chemotherapy in Patients with Diffuse Large B Cell Lymphoma Katharina Lisenko,

Bridge to transplant following Bv+Bs regimen.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Anti-CD20-IL-21 fusokine: the tail wags the dog

An algorithmic approach to FL

CR-rate ratios with 95% CIs

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

How I treat early-relapsing follicular lymphoma

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

by Lapo Alinari, and Kristie A. Blum

Initial treatment of CLL: integrating biology and functional status

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Optimizing therapy for nodal marginal zone lymphoma

Is Skull-Base to Proximal Thigh PET/CT Enough

Cold agglutinin disease

Presentation transcript:

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal Blood Volume 132(8):777-781 August 23, 2018 ©2018 by American Society of Hematology

Victor A. Chow et al. Blood 2018;132:777-781 ©2018 by American Society of Hematology

Proposed schema for use of anti-CD19 CAR T-cell therapy in clinical practice. Proposed schema for use of anti-CD19 CAR T-cell therapy in clinical practice. PR, partial response; Rx, treatment. *Proceed to salvage 2 or CAR T-cell therapy. †Proceed to salvage 2, CAR T-cell therapy, or ASCT. ‡Proceed to CAR T-cell therapy ± salvage 3. Victor A. Chow et al. Blood 2018;132:777-781 ©2018 by American Society of Hematology